DOCK7 and neoplasm: EGFR triggers multiple downstream signaling pathways (such as the PI3K-AKT-mTOR pathway), which are involved in cell proliferation, survival, and tumor invasion. The level of its ligand can affect tumor invasiveness by inhibiting the DOCK−7 Rho GTP pathway.